Skip to content
lifestyle.duovoltart.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Inhibrx Biosciences, Inc.
Inhibrx Reports Second Quarter 2026 Financial Results
August 13, 2026
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
July 16, 2026
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
June 15, 2026
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
April 21, 2026
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
April 20, 2026
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
March 19, 2026
Inhibrx Announces Participation in Upcoming Scientific Conference
March 2, 2026